Biopharmaceutical News and Research

RSS

Avecia Biologics to be acquired by Merck

Merck & Co. Inc., (operating in the United Kingdom as MSD) and Avecia Investments Limited today announced that they have entered into a definitive agreement by which Merck will acquire the biologics business of the Avecia group through a Merck affiliate (Merck Sharp & Dohme (Holdings) Limited or "MSD"). Avecia Biologics is a contract manufacturing organization with specific expertise in microbial-derived biologics. Financial details of the transaction were not disclosed.

17 Dec 2009

Cubist Pharmaceuticals acquires Calixa Therapeutics

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company has completed its previously announced acquisition of Calixa Therapeutics Inc.,

17 Dec 2009

Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced top-line efficacy and safety results from a Phase 2b clinical trial of XIAFLEX(TM) for the treatment of Peyronie's disease.

17 Dec 2009

Phase 3 registration clinical trial for perifosine initiated by Keryx Biopharmaceuticals

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the initiation, by its partner Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX), of a Phase 3 registration clinical trial for perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor, in relapsed/refractory multiple myeloma patients.

16 Dec 2009

Nanotherapeutics acquires Ramoplanin clinical program from Oscient Pharmaceuticals

Nanotherapeutics, Inc., a privately held biopharmaceutical company, announced that it has acquired in bankruptcy proceedings two late stage clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation and PRX-3140 from EPIX Pharmaceuticals, Inc.

16 Dec 2009

EMD Serono, Brigham and Women's Hospital collaborate in MS research

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced a strategic collaboration with Brigham and Women's Hospital in Boston, to advance basic and clinical research in multiple sclerosis (MS), with the goal of generating new and innovative discoveries that advance treatment for people living with this condition. The multi-faceted agreement will run for up to 5 years, with the potential to renew the alliance thereafter. Both parties decided not to disclose financial details.

16 Dec 2009

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Æterna Zentaris Inc., a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the initiation, by its partner Keryx Biopharmaceuticals Inc., of a Phase 3 registration clinical trial for perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor, in relapsed/refractory multiple myeloma patients.

16 Dec 2009

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced top-line efficacy and safety results for the phase IIb clinical trial for XIAFLEX™ (collagenase clostridium histolyticum) in the treatment of Peyronie's disease.

16 Dec 2009

Biotage expands direct sales coverage

Biotage is expanding its direct sales coverage and will begin selling SPE products directly into non-pharma application areas within the UK starting January 18, 2010. Sales to non-pharmaceutical based markets and customers have previously been managed by a distributor.

16 Dec 2009

ThromboGenics completes enrollment in second microplasmin Phase III trial

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.

16 Dec 2009

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the presentation of a poster at the annual American Society of Hematology (ASH) meeting that describes the preclinical activity of Arno’s drug candidate AR-42 against leukemia stem cells (LSCs).

16 Dec 2009

Pfizer to co-promote Actos with Tianjin Takeda Pharmaceuticals in China

Takeda Pharmaceutical Company Limited (“Takeda”) and Pfizer Inc. (“Pfizer”) announced that they have entered into an agreement under which Pfizer in China will co-promote Takeda’s Actos® (pioglitazone HCl) with Tianjin Takeda Pharmaceuticals in China.

15 Dec 2009

Dyadic International enters into collaboration agreement with The Scripps Research Institute

Dyadic International, Inc. ("Dyadic") announced today that it has extended its collaboration with The Scripps Research Institute ("Scripps") by entering into an agreement with Scripps to re-annotate the genome of Dyadic's patented and proprietary C1 fungus ("C1").

15 Dec 2009

UCB offers tips for managing rheumatoid arthritis during festive season

A third of women living with rheumatoid arthritis say their disease impacts their enjoyment of the festive season - Women living with rheumatoid arthritis find shopping for gifts, preparing holiday food, writing cards and wrapping presents most difficult to do - Nearly two thirds of women living with rheumatoid arthritis experience pain daily

14 Dec 2009

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

Cubist Pharmaceuticals, Inc. a leading acute care therapeutics company, announced today the signing of a definitive agreement under which Cubist has agreed to acquire privately held Calixa Therapeutics Inc., a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens.

14 Dec 2009

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of positive trastuzumab-DM1 (T-DM1) clinical data at the 32nd Annual San Antonio Breast Cancer Symposium (Abstract #710).

14 Dec 2009

Maxygen extends 'Dutch Auction' tender offer for share repurchase program

Maxygen, Inc., a biopharmaceutical company focused on the development of improved versions of protein drugs, today announced that it has extended the expiration date for its modified "Dutch Auction" tender offer to repurchase 6,557,377 shares of its common stock, which was commenced on November 13, 2009.

13 Dec 2009

"Checklists" for evaluating comparative effectiveness research

A new report released today by the National Pharmaceutical Council (NPC) provides guidance in the evaluation of comparative effectiveness research (CER), including easy-to-use "checklists" that help make sure such studies can be used to improve the dialogue between health care providers and patients, as well as better inform health care decision-making.

11 Dec 2009

Circassia raises GBP15M for development of its novel allergy T-cell vaccines portfolio

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has completed a GBP15 million ($25 million) fundraising. The investment round, which was led by Imperial Innovations and supported by existing shareholders including Invesco Perpetual and Lansdowne Partners, was significantly oversubscribed and is the company's third successful fundraising.

11 Dec 2009

Pfizer extends its patient assistance program for unemployed and uninsured Americans

Pfizer today announced it will extend its MAINTAIN™ (Medicines Assistance for Those who Are in Need) patient assistance program for an additional year, through December 31, 2010. In addition to the more than 70 Pfizer primary care medicines currently available through MAINTAIN, Pfizer will extend the benefits of MAINTAIN to many legacy Wyeth medicines.

11 Dec 2009

Biopharmaceutical News and Research

Avecia Biologics to be acquired by Merck

Cubist Pharmaceuticals acquires Calixa Therapeutics

Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced

Phase 3 registration clinical trial for perifosine initiated by Keryx Biopharmaceuticals

Nanotherapeutics acquires Ramoplanin clinical program from Oscient Pharmaceuticals

EMD Serono, Brigham and Women's Hospital collaborate in MS research

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Biotage expands direct sales coverage

ThromboGenics completes enrollment in second microplasmin Phase III trial

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Pfizer to co-promote Actos with Tianjin Takeda Pharmaceuticals in China

Dyadic International enters into collaboration agreement with The Scripps Research Institute

UCB offers tips for managing rheumatoid arthritis during festive season

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

Maxygen extends 'Dutch Auction' tender offer for share repurchase program

"Checklists" for evaluating comparative effectiveness research

Circassia raises GBP15M for development of its novel allergy T-cell vaccines portfolio

Pfizer extends its patient assistance program for unemployed and uninsured Americans

Event guide: World ADC Asia eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News